Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Aug 1;34(4):141-146.
doi: 10.1097/MOL.0000000000000878. Epub 2023 Mar 17.

Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action

Núria Roglans  1   2   3 , Juan Carlos Laguna  1   2   3 , Marta Alegret  1   2   3
Affiliations
Review

Bempedoic acid for nonalcoholic fatty liver disease: evidence and mechanisms of action

Núria Roglans et al. Curr Opin Lipidol. .

Abstract

Purpose of review: Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent progressive condition that lacks a specific pharmacological treatment. ATP-citrate lyase (ACLY) is one of the emergent targets for the treatment of NAFLD. This review aims to summarize the role of ACLY in NAFLD, provide evidence of the beneficial effects of the ACLY inhibitor bempedoic acid (BemA) in NAFLD and discuss the mechanisms involved.

Recent findings: BemA is effective in reducing hepatic steatosis in several animal models that recapitulate different stages of the disease. Thus, in a dietary model of simple hepatic steatosis in female rats, BemA abrogates the accumulation of liver fat. Apart from ACLY inhibition, BemA has several functions in the liver that contribute to the antisteatotic effect: inhibition of ketohexokinase, induction of patatin-like phospholipase domain-containing protein 3 and increases in both fatty acid β-oxidation activity and hepatic H 2 S production. In models of the advanced phases of NAFLD, BemA reduces not only steatosis, but also ballooning, lobular inflammation and hepatic fibrosis, by mechanisms involving both hepatocytes and hepatic stellate cells.

Summary: BemA, an ACLY inhibitor currently approved for the treatment of hypercholesterolemia, may be a useful drug to treat NAFLD through its antisteatotic, anti-inflammatory and antifibrotic effects.

PubMed Disclaimer

References

    1. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings. Endocr Pract 2022; 28:528–562.
    1. Saiman Y, Duarte-Rojo A, Rinella ME. Fatty liver disease: diagnosis and stratification. Annu Rev Med 2022; 73:529–544.
    1. Anstee QM, Reeves HL, Kotsiliti E, et al. From NASH to HCC: current concepts and future challenges. Nat Rev Gastroenterol Hepatol 2019; 16:411–428.
    1. Mazzolini G, Sowa JP, Atorrasagasti C, et al. Significance of simple steatosis: an update on the clinical and molecular evidence. Cells 2020; 9:1–19.
    1. Birerdinc A, Stepanova M, Pawloski L, et al. Caffeine is protective in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther 2012; 35:76–82.

Publication types

Substances